Sector News

China Pledges to Speed Entry of US Pharmaceuticals

December 19, 2014
Life sciences
(Associated Press) – China promised Thursday to speed up imports of pharmaceuticals and medical devices from the United States and enforce its anti-monopoly laws equally among Chinese and foreign companies.
 
Those commitments were announced at an annual trade meeting between the two countries that took place in Chicago.
 
An assistant minister of commerce, Zhang Xiangchen, told reporters China would work to streamline the review and approval process for U.S. products in the pharmaceutical and medical industries and address a backlog within two to three years.
 
“We will also reduce as much as possible needless clinical trials,” he said through an interpreter.
 
Topics at this year’s U.S.-China Joint Commission on Commerce and Trade also included protection of intellectual property and trade secrets as well as ensuring there’s a level playing field for U.S. companies in China.
 
The yearly gatherings are meant to resolve disputes before they disrupt trade.
 
The American side was led by U.S. Commerce Secretary Penny Pritzker and U.S. Trade Representative Michael Froman.
 
Pritzker said China’s promises in the medical and pharmaceutical areas “should lead to (an) increase in U.S. exports and U.S. jobs in these two important sectors.”
 
She also called Chinese movement on antitrust laws “significant.” She and a panel of Chinese officials, who spoke separately, provided few details.
 
Business groups have expressed concern about a wave of Chinese anti-monopoly investigations, suggesting Beijing is improperly using those probes to pressure foreign companies to cut prices or change business practices.
 
Mentioning one specific step, Zhang said China would try, when possible, to allow U.S. legal counsel for American companies to attend meetings in antitrust proceedings.
 
Despite such pledges at the yearly gatherings, American companies have complained of slow progress and are pushing for faster strides toward an investment treaty between the two countries. A treaty would help make operating conditions in China’s state-dominated economy clearer and more predictable, they say.
 
Pritzker acknowledged while summing up Thursday’s talks that “none of this is to say that we got all the outcomes we wanted or that all the outcomes are perfect.”
 
Trade between the two countries totaled $617 billion last year, and U.S. firms have rushed to invest in China.
 
But Beijing faces complaints that it’s backtracking on market-opening pledges by tightening restrictions on foreign investment in technology, agriculture and other industries. Business groups argue that China improperly uses industrial standards and other regulation to shield its own companies from competition.
 
The Communist Party leadership under President Xi Jinping has promised to give market forces a bigger role but has yet to make major steps toward opening more industries such as banking, telecoms and logistics that are dominated by state companies.
 
For their part, the Chinese delegation pressed the U.S. side to allow China to import American oil and gas equipment.
 
Pritzker called that “a work in progress” and said the U.S. could agree to an export license for one product, perhaps two.
 
By Jason Keyser

comments closed

Related News

October 10, 2021

Nutraceutical giants’ partnerships inject life back into industry at Vitafoods

Life sciences

Some of industry’s biggest players are joining forces to bring cost-effective yet scientifically backed offerings to the nutraceuticals market. Co-creation is reinvigorating supplement innovation, pairing together companies’ diverse expertise, sales networks and clinical trial investments.

October 10, 2021

Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africa

Life sciences

GlaxoSmithKline has spent many years developing and testing its world-first malaria vaccine, but even after a positive recommendation from European regulators in 2015, the shot still isn’t widely deployed. That’s set to change with the World Health Organization’s (WHO’s) blessing for the vaccine.

October 10, 2021

Henrietta Lacks’ estate sues Thermo Fisher for continued sale of HeLa cells without family consent

Life sciences

A sample of Henrietta Lacks’ tissue was taken from her cervix without her consent while she was undergoing cancer treatment at Johns Hopkins Hospital in 1951. Her cells have subsequently been used to develop the polio vaccine, HPV vaccines and gene-mapping techniques and continue to be sold for research purposes by Thermo Fisher Scientific.

Send this to a friend